Citation	Factors included in multivariable (multivariate) analysis
Akahira 2001	Residual disease, histology and performance status
Aletti 2006	Residual disease, age, American Society of Anesthesiology (ASA) score, histological grade, operative time and aggressive surgery
Ataseven 2016	Age, performance status, residual tumour, tumour stage and ascites
Bristow 2011	Race, tumour grade 3, non‐serous histology, ASA score > 3, surgical complexity score, serum albumin < 3.0 g/dL, platinum‐based therapy, residual disease and perioperative morbidity
Chan 2003	Residual disease, age (older versus younger), stage (IV versus III) and performance status (1 to 2 versus 0)
Chang 2012a	Stage (IV), surgical procedure, residual disease and age
Chang 2012b	Residual disease, type of surgery, performance of lymphadenectomy and age
Chi 2001	Residual disease, age, stage (IIIC and IV versus IIIA/IIIB) and ascites (yes versus no)
Chi 2006	Residual disease, age and ascites
Cuylan 2018	Age, maximal cytoreduction and stage
Eisenkop 2003	Residual disease and sum of rankings
Feng 2016	Age, FIGO stage, residual disease and TTC
Hofstetter 2013	Interval from surgery to start of chemotherapy (≤ 28 versus < 28 days), stage (III versus IV), residual disease, age and extent of surgery
Kahl 2017	ACCI, ECOG PS, FIGO stage, surgical complexity score, blood loss, residual disease and duration of surgery
Klar 2016	Age, ECOG, BMI, stage, grading, residual tumour and histology
Langstraat 2011	Creatinine > 1.2 mg/dL, surgical complexity score, residual disease, stage IV disease and age
Luger 2020	Age (cat), CA‐125, paraaortic nodes, FIGO, cardiophrenic lymph nodes dimension, residual disease
McGuire 1995	Residual disease, age, GOG performance status, histological subtype, stage or residual disease and measurable disease
Melamed 2017a	Age, race/ethnicity, stage, region, insurance status, treating facility type, hospital annual ovarian cancer volume, residual disease and presence of comorbidities
Melamed 2017b
Paik 2018	Age, CA‐125 level (U/mL), FIGO stage, residual disease and normal‐sized ovary
Peiretti 2010	Age, stage IV vs IIIC and any residual disease
Peiretti 2012	Age, stage, histology, grade, presence of ascites and residual tumour at end of surgery
Polterauer 2012	Tumour stage, residual tumour, histological grade, histological type and age
Shim 2016	Not reported (abstract)
Tewari 2016	Age, race/ethnicity, performance status, grade, stage, histology,ascites, CA 125 (µg/ml), tumour residual and time from surgery to initiation of chemotherapy
Tseng 2018	Age, albumin, stage, ASA score, histology, BRCA status, OR Tumour Index, residual disease and postop IP chemotherapy
Van Geene 1996	Residual disease, performance status and pattern of spread
Wimberger 2010	Age, performance status, histology, residual tumour size, peritoneal carcinomatosis and stage IV disease site
Winter 2007	Residual disease, age (discrete), race, GOG performance status, histology and tumour grade
Winter 2008	Residual disease, histology and stage IV disease site